$ATNM
Actinium Pharmaceuticals, Inc. Stock $atnm

$atnm Overview Financials Valuation SEC Filings Company Website

2023 Form 10-K Financial Statement

#000121390024028038 Filed on March 29, 2024

Income Statement

Concept	2023	2022
Revenue	$81.00K	$1.030M
YoY Change	-92.14%	-9.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$13.30M	$11.99M
YoY Change	10.94%	48.73%
% of Gross Profit
Research & Development	$38.50M	$23.14M
YoY Change	66.39%	28.94%
% of Gross Profit
Depreciation & Amortization	$790.0K	$152.0K
YoY Change	419.74%	-70.99%
% of Gross Profit
Operating Expenses	$52.00M	$35.13M
YoY Change	48.01%	34.57%
Operating Profit	-$51.92M	-$34.10M
YoY Change	52.24%	36.61%
Interest Expense	$3.102M	$1.087M
YoY Change	185.37%	472.11%
% of Operating Profit
Other Income/Expense, Net	$3.102M	$1.087M
YoY Change	185.37%	472.11%
Pretax Income	-$48.82M	-$33.02M
YoY Change	47.86%	33.27%
Income Tax
% Of Pretax Income
Net Earnings	-$48.82M	-$33.02M
YoY Change	47.86%	33.27%
Net Earnings / Revenue	-60269.14%	-3205.53%
Basic Earnings Per Share	-$1.83	-$1.37
Diluted Earnings Per Share	-$1.84	-$1.37
COMMON SHARES
Basic Shares Outstanding	26.60M shares	24.14M shares
Diluted Shares Outstanding	26.60M shares	24.14M shares

Balance Sheet

Concept	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.68M	$108.9M
YoY Change	-29.6%	39.93%
Cash & Equivalents	$76.68M	$108.9M
Short-Term Investments
Other Short-Term Assets	$1.586M	$2.032M
YoY Change	-21.95%	5.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$78.26M	$110.9M
YoY Change	-29.46%	39.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.869M	$2.948M
YoY Change	-2.68%	361.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$313.0K	$302.0K
YoY Change	3.64%
Total Long-Term Assets	$3.182M	$3.250M
YoY Change	-2.09%	408.61%
TOTAL ASSETS
Total Short-Term Assets	$78.26M	$110.9M
Total Long-Term Assets	$3.182M	$3.250M
Total Assets	$81.45M	$114.2M
YoY Change	-28.68%	42.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.953M	$10.13M
YoY Change	-21.49%	83.02%
Accrued Expenses	$530.0K	$494.0K
YoY Change	7.29%	101.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.00K	$4.000K
YoY Change	175.0%	-93.55%
Total Short-Term Liabilities	$8.494M	$10.63M
YoY Change	-20.08%	55.38%
LONG-TERM LIABILITIES
Long-Term Debt	$19.00K	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$36.55M	$37.08M
YoY Change	-1.43%
Total Long-Term Liabilities	$36.57M	$37.08M
YoY Change	-1.38%	1236000.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.494M	$10.63M
Total Long-Term Liabilities	$36.57M	$37.08M
Total Liabilities	$45.07M	$47.71M
YoY Change	-5.54%	597.22%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.38M	$66.48M
YoY Change
Total Liabilities & Shareholders Equity	$81.45M	$114.2M
YoY Change	-28.68%	42.05%

Cashflow Statement

Concept	2023	2022
OPERATING ACTIVITIES
Net Income	-$48.82M	-$33.02M
YoY Change	47.86%	33.27%
Depreciation, Depletion And Amortization	$790.0K	$152.0K
YoY Change	419.74%	-70.99%
Cash From Operating Activities	-$47.34M	$8.644M
YoY Change	-647.61%	-141.43%
INVESTING ACTIVITIES
Capital Expenditures	$153.0K	$366.0K
YoY Change	-58.2%	-375.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$153.0K	-$366.0K
YoY Change	-58.2%	175.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$14.87M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.87M	$23.11M
YoY Change	-35.65%	-34.39%
NET CHANGE
Cash From Operating Activities	-47.34M	$8.644M
Cash From Investing Activities	-153.0K	-$366.0K
Cash From Financing Activities	14.87M	$23.11M
Net Change In Cash	-32.62M	$31.39M
YoY Change	-203.92%	120.69%
FREE CASH FLOW
Cash From Operating Activities	-$47.34M	$8.644M
Capital Expenditures	$153.0K	$366.0K
Free Cash Flow	-$47.49M	$8.278M
YoY Change	-673.67%	-139.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36374
CY2023	dei	Entity Registrant Name EntityRegistrantName	ACTINIUM PHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	74-2963609
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Park Ave., 23rd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10017
CY2023	dei	City Area Code CityAreaCode	(646)
CY2023	dei	Local Phone Number LocalPhoneNumber	677-3870
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.001
CY2023	dei	Trading Symbol TradingSymbol	ATNM
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	200262958	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29396411	shares
CY2023	dei	Auditor Name AuditorName	Marcum llp
CY2023	dei	Auditor Location AuditorLocation	Houston, Texas
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76677000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108910000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	396000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1586000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1636000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	78263000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	110942000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	694000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	487000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	550000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	604000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	313000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	302000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2289000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2341000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	30000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3000	usd
CY2023Q4	us-gaap	Assets Assets	81445000	usd
CY2022Q4	us-gaap	Assets Assets	114192000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	7953000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	10130000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	530000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	494000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	11000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	4000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8494000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10628000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	35000000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	35000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1553000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2083000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	19000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	45066000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	47711000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27634213	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27634213	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25674823	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25674823	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	28000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	26000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	373934000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	355220000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-337583000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288765000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	36379000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	66481000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81445000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	114192000	usd
CY2023	us-gaap	Revenues Revenues	81000	usd
CY2022	us-gaap	Revenues Revenues	1030000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38670000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23135000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13331000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11999000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	52001000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	35134000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-51920000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-34104000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3102000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1087000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3102000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1087000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-48818000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33017000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.83
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26604045	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24141545	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	73545000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2795000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	23158000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33017000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	66481000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3842000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14612000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	262000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-48818000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	36379000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-48818000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33017000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3842000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2795000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	790000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	699000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-49000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	158000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2177000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4595000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-998000	usd
CY2022	atnm	Increase Decrease In Longterm License Revenues Deferred IncreaseDecreaseInLongtermLicenseRevenuesDeferred	35000000	usd
CY2023	atnm	Increase Decrease In Operating Lease Rightofuse Assets IncreaseDecreaseInOperatingLeaseRightofuseAssets	-527000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-494000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-272000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47335000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8644000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	153000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	366000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-153000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-366000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	4000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	49000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14612000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23158000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	262000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14870000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23109000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-32618000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	31387000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109608000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78221000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76990000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109608000	usd
CY2023	atnm	Rightofuse Assets Obtained In Exchange For Lease Liabilities RightofuseAssetsObtainedInExchangeForLeaseLiabilities	30000	usd
CY2022	atnm	Rightofuse Assets Obtained In Exchange For Lease Liabilities RightofuseAssetsObtainedInExchangeForLeaseLiabilities	2605000	usd
CY2022	atnm	Acquisition Of Equipment Financed By Security Deposit AcquisitionOfEquipmentFinancedBySecurityDeposit	50000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates in Financial Statement Presentation -</b> The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	76677000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	108910000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	396000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	313000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	302000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	76990000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	109608000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7192000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5164000	shares
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.05	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.05	pure
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	614000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	684000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	746000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	887000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	226000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	65000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1586000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1636000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	694000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	487000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	550000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	604000	usd
CY2023	us-gaap	Depreciation Depreciation	207000	usd
CY2022	us-gaap	Depreciation Depreciation	152000	usd
CY2023	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	5 years 2 months
CY2023	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2027-07-30
CY2023	us-gaap	Payments For Rent PaymentsForRent	600000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	691000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	584000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	3000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	55000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	usd
CY2023	us-gaap	Lease Cost LeaseCost	3000	usd
CY2022	us-gaap	Lease Cost LeaseCost	57000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	606000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	352000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	4000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	49000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2605000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	30000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023	atnm	Schedule Of Weighted Average Discount Rate ScheduleOfWeightedAverageDiscountRate	weighted average discount rates used at the time that the leases were evaluated:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td>Weighted average discount rates:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.2</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.048	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.062	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	618000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	11000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	630000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	11000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	643000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	11000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	380000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2271000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	33000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	188000	usd
CY2023Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	3000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2083000	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	30000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	900000	usd
CY2023	us-gaap	Other Income OtherIncome	100000	usd
CY2022	us-gaap	Other Income OtherIncome	100000	usd
CY2022Q2	us-gaap	Advance Royalties AdvanceRoyalties	35000000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	35000000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	35000000	usd
CY2012Q2	atnm	Milestone Payment MilestonePayment	1000000	usd
CY2023	atnm	Description Of Royalty Payment To Related Party DescriptionOfRoyaltyPaymentToRelatedParty	Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.
CY2023	atnm	Net Sales NetSales	0.02	pure
CY2023	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1900000	shares
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	3500000	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	309000	shares
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	60000	shares
CY2023	atnm	Stock Options Exercised Shares Of Common Stock StockOptionsExercisedSharesOfCommonStock	44000	shares
CY2023	atnm	Compensation Expense Related To Stock Options CompensationExpenseRelatedToStockOptions	3200000	usd
CY2022	atnm	Compensation Expense Related To Stock Options CompensationExpenseRelatedToStockOptions	2500000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	325000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.96
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	325000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.96
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	5000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.31
CY2023	atnm	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod	25000	shares
CY2023	atnm	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue	7.31
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	305000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.89
CY2022Q3	atnm	Class Of Warrants Shares Expired ClassOfWarrantsSharesExpired	600000	shares
CY2017Q3	atnm	Underwritten Offering Shares UnderwrittenOfferingShares	700000	shares
CY2017Q3	atnm	Warrants To Purchase Shares Of Common Stock warrantsToPurchaseSharesOfCommonStock	600000	shares
CY2017Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	22.5
CY2023	atnm	Exercisable Period Years ExercisablePeriodYears	P5Y
CY2023	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	31.5
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	41698000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	44233000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	8219000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1512000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1334000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	20509000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	17247000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	18684000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	13210000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-57000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	69000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	90566000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	76093000	usd
CY2023Q4	atnm	Deferred Tax Assets Valuation Allowances DeferredTaxAssetsValuationAllowances	90600000	usd
CY2022Q4	atnm	Deferred Tax Assets Valuation Allowances DeferredTaxAssetsValuationAllowances	76100000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies Foreign IncomeTaxReconciliationTaxContingenciesForeign	165100000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	104800000	usd
CY2023Q4	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	60300000	usd
CY2023	us-gaap	Tax Credit Carryforward Limitations On Use TaxCreditCarryforwardLimitationsOnUse	limited to 80% of their value if used in a tax year ending after January 1, 2023.
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies State And Local IncomeTaxReconciliationTaxContingenciesStateAndLocal	283000000	usd
CY2023	us-gaap	Research And Development Arrangement With Federal Government Costs Incurred Net ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet	36900000	usd
CY2023	atnm	Accumulated Gross Amount AccumulatedGrossAmount	79600000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10252000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.21	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6943000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Exempt Income EffectiveIncomeTaxRateReconciliationTaxExemptIncome	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1743000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.036	pure
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4863000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.147	pure
CY2023	atnm	Income Tax Reconciliation Deferredtrue Up IncomeTaxReconciliationDeferredtrue-up	-176000	usd
CY2023	atnm	Effective Income Tax Reconciliation Deferred True Ups EffectiveIncomeTaxReconciliationDeferredTrueUps	0.004	pure
CY2022	atnm	Income Tax Reconciliation Deferredtrue Up IncomeTaxReconciliationDeferredtrue-up	-89000	usd
CY2022	atnm	Effective Income Tax Reconciliation Deferred True Ups EffectiveIncomeTaxReconciliationDeferredTrueUps	0.003	pure
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3263000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.067	pure
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2711000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.082	pure
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	608000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.012	pure
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	934000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.028	pure
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14474000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.297	pure
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13494000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.408	pure
CY2023	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	1800000	usd
CY2023Q4	atnm	Net Proceeds NetProceeds	14700000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.83
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24141545	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26604045	shares
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2023	atnm	Increase Decrease In Longterm License Revenues Deferred IncreaseDecreaseInLongtermLicenseRevenuesDeferred		usd
CY2022	atnm	Increase Decrease In Operating Lease Rightofuse Assets IncreaseDecreaseInOperatingLeaseRightofuseAssets		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	atnm	Acquisition Of Equipment Financed By Security Deposit AcquisitionOfEquipmentFinancedBySecurityDeposit		usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent		usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability		usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001388320

Files In Submission

Name	View Source	Status
0001213900-24-028038-index-headers.html	Edgar Link	pending
0001213900-24-028038-index.html	Edgar Link	pending
0001213900-24-028038.txt	Edgar Link	pending
0001213900-24-028038-xbrl.zip	Edgar Link	pending
atnm-20231231.xsd	Edgar Link	pending
f10k2023ex23-1_act.htm	Edgar Link	pending
f10k2023ex31-1_act.htm	Edgar Link	pending
f10k2023ex31-2_act.htm	Edgar Link	pending
f10k2023ex32-1_act.htm	Edgar Link	pending
f10k2023ex32-2_act.htm	Edgar Link	pending
f10k2023ex97-1_act.htm	Edgar Link	pending
f10k2023_actinium.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
atnm-20231231_def.xml	Edgar Link	unprocessable
f10k2023_actinium_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
atnm-20231231_cal.xml	Edgar Link	unprocessable
atnm-20231231_pre.xml	Edgar Link	unprocessable
atnm-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATNM
Actinium Pharmaceuticals, Inc. Stock $atnm

2023 Form 10-K Financial Statement

#000121390024028038 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATNM Actinium Pharmaceuticals, Inc. Stock $atnm

2023 Form 10-K Financial Statement

#000121390024028038 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATNM
Actinium Pharmaceuticals, Inc. Stock $atnm